Acadia Pharmaceuticals Inc. Files 8-K
Ticker: ACAD · Form: 8-K · Filed: May 20, 2025 · CIK: 1070494
| Field | Detail |
|---|---|
| Company | Acadia Pharmaceuticals Inc (ACAD) |
| Form Type | 8-K |
| Filed Date | May 20, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, other-events
Related Tickers: ACAD
TL;DR
ACADIA entered a material definitive agreement and reported other events on 5/15.
AI Summary
On May 15, 2025, Acadia Pharmaceuticals Inc. entered into a material definitive agreement. The company also reported on other events on this date. The filing was made on May 20, 2025.
Why It Matters
This filing indicates Acadia Pharmaceuticals Inc. has entered into a significant agreement and is reporting other material events, which could impact its business operations and stock.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting a material definitive agreement and other events, without immediate negative financial implications disclosed.
Key Players & Entities
- ACADIA PHARMACEUTICALS INC (company) — Registrant
- May 15, 2025 (date) — Date of earliest event reported
- May 20, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of Incorporation
- 000-50768 (filing_id) — SEC File Number
- 06-1376651 (tax_id) — IRS Employer Identification No.
- 12830 El Camino Real , Suite 400 (address) — Principal Executive Offices
- San Diego (city) — Principal Executive Offices
- California (state) — Principal Executive Offices
- 92130 (zip_code) — Principal Executive Offices
FAQ
What type of material definitive agreement did Acadia Pharmaceuticals Inc. enter into?
The filing states that Acadia Pharmaceuticals Inc. entered into a 'Material Definitive Agreement' but does not specify the nature of the agreement in the provided text.
What are the 'Other Events' reported by Acadia Pharmaceuticals Inc. on May 15, 2025?
The provided text indicates that 'Other Events' were reported on May 15, 2025, but does not detail what those events are.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on May 20, 2025.
Where are Acadia Pharmaceuticals Inc.'s principal executive offices located?
Acadia Pharmaceuticals Inc.'s principal executive offices are located at 12830 El Camino Real, Suite 400, San Diego, California, 92130.
What is Acadia Pharmaceuticals Inc.'s SEC file number?
Acadia Pharmaceuticals Inc.'s SEC file number is 000-50768.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 20, 2025 regarding ACADIA PHARMACEUTICALS INC (ACAD).